YD Bio

YD Bio is a diversified biotech company with a multi-platform strategy spanning diagnostics, therapeutics, and clinical trial services. Its core focus is on DNA methylation-based early cancer detection, developed in partnership with EG Biomed, and exosome-based regenerative therapies for ophthalmology, developed with 3D Global Biotech. The company is publicly listed on Nasdaq, leverages strategic partnerships for R&D and commercialization, and operates a revenue-generating clinical trial supply business that supports its development-stage pipeline.

DNA methylation analysis for liquid biopsy cancer detection; Limbal stem cell-derived exosomes for regenerative ophthalmology.

In early cancer detection, YD Bio faces competition from large, established players like Grail (Illumina), Exact Sciences, and Freenome. In the dry eye and regenerative ophthalmology space, it competes with major pharmaceutical companies (e.g., Allergan/AbbVie, Novartis) and medical device firms, making differentiation and market penetration challenging.